Limb girdle muscular dystrophy type 2B masquerading as inflammatory myopathy: case report
© Jethwa et al.; licensee BioMed Central Ltd. 2013
Received: 21 December 2012
Accepted: 23 April 2013
Published: 3 May 2013
Skip to main content
© Jethwa et al.; licensee BioMed Central Ltd. 2013
Received: 21 December 2012
Accepted: 23 April 2013
Published: 3 May 2013
Limb girdle muscular dystrophy type 2B is a rare subtype of muscular dystrophy, the predominant feature of which is muscle weakness. The disease is caused by an autosomal recessively inherited reduction/absence of muscle dysferlin due to a mutation in dysferlin gene at 2p12-14. We report a 10 year old boy who presented with severe non-transient right knee pain and swelling, which later became bilateral. His pain was worst in the morning and during rest. Blood tests revealed markedly raised creatine kinase values (highest 22, 297 U/l), raising the possibility of an inflammatory myositis. MRI showed bilateral asymmetrical muscle involvement of thighs and calves with oedematous changes mimicking the imaging appearances of inflammatory myositis. CRP and ESR levels were consistently within normal limits. Over several months his knee pain worsened and limited walking. Muscle biopsy revealed a severe reduction of dysferlin immunostaining, indicating the diagnosis, which was confirmed by 2 compound heterozygous pathogenic mutations in the dysferlin gene. It is not unusual for this subtype of the disease to mimic myositis: however, significant pain is a rare presenting symptom. Given the significant overlap between this form of muscular dystrophy and inflammatory myopathies, a high index of suspicion is needed to ensure an accurate and timely diagnosis. Furthermore, characteristic inflammatory-related morning pain should not rule out consideration of non-inflammatory causes.
Muscle pain is a common presenting symptom to paediatric rheumatology clinics. The overlap between differential diagnoses can sometimes make such cases challenging. Limb girdle muscular dystrophies (LGMD) are a rare group of conditions, the predominant feature of which is weakness of lower and upper limbs, although symptoms may predominate in one muscle group. The typical presenting symptom is difficulty climbing stairs. LGMD type 2B is an autosomal recessive condition due to homozygous or compound heterozygous mutations in the dysferlin gene (DYSF) on 2p12-14, leading to a deficiency or absence of the protein, dysferlin. This protein is primarily found in skeletal muscle but can also be found in cardiac muscle . The onset age of LGMD type 2 is usually 12–39 years, typically presenting with pelvic girdle weakness . Pain is not a typical feature however, if present, is usually mild, transient and follows exertion. Creatine kinase (CK) levels are markedly raised and can be 10–72 times normal values [1–3]. At times, genetically inherited myopathies can mimic inflammatory myopathy. Pimentel et al. (2008) describe an adult case of LGMD type 2 subject to misdiagnosis of polymyositis, despite having consanguinous parents and also two siblings with similar symptoms of muscle weakness .
Although disease caused by a reduction/absence in dysferlin typically demonstrates a slow indolent course , in some cases symptoms may be highly debilitating . Nyugen et al. (2007) describe a patient with a dysferlinopathy who had complete loss of ambulation just five years after symptom onset . Given the wide spectrum of disease severity with dysferlinopathies, it is vital that healthcare professionals are aware of atypical presentations of the condition. A high index of suspicion is needed in order for an accurate diagnosis to ensure adequate and timely treatment in order to help minimize progression.
Here we report an atypical case of LGMD type 2B presenting at the age of ten years with significant, non-transient knee pain which was worst in the morning.
The patient was a boy of West African origin born to non-consanguineous parents who presented aged 10 years with a one year history of bilateral knee pain, radiating down the legs. The pain started in the right knee after a long walk, was of fairly rapid onset, and was associated with swelling. Within a few weeks, his left knee subsequently also became painful and swollen. The pain was very localised to the knee and was continuous but with intermittent exacerbations, being worse in the mornings and during rest.
Non-steroidal anti-inflammatory medication prescribed by his general practitioner provided only mild symptomatic relief. Two months after symptom onset, he was reviewed by his paediatrician. Investigations demonstrated ESR and CRP values were within normal limits (5 mm/hr and 4 mg/L, respectively), as was the ACE level. He was negative for sickle cell trait. Knee MRI scan showed a small joint effusion and no synovial thickening. Aspiration and culture of synovial fluid was negative and remarkably noted as being almost acellular. Around this time a dark, ecchymosis-like rash around the affected knee developed, which was possibly secondary to warm compresses. The general paediatric team prescribed intramuscular Depo-Medrone 80mg, which only provided 5–6 days of relief. Over the following 9 months the patient was readmitted several more times with severe pain. He had no other rash, no high fevers, no eye problems other than an episode of conjunctivitis a month prior to the onset of pain. He had no ulcers, no alopecia, no profound fatigue, no soreness of the mouth, no breathlessness and no change in bowel habit.
He was an only child, born by a normal vaginal delivery at 42 weeks gestation. Both parents have sickle cell trait. There was no family history of autoimmune disease and no relevant past medical history.
On examination during his first Paediatric rheumatology appointment, he was on the 99th and 98th centile for his weight and height, respectively. He was afebrile with no mouth ulcers, nail fold abnormalities and no lymphadenopathy. Cardiovascular and respiratory examinations were unremarkable. He had a small right knee effusion with some pain on flexion. The knee was held in a few degrees of flexion, although it was possible to get the knee to neutral.
One month later, he was admitted to hospital following worsening of his knee pain. At this point he reported increasing difficulty standing up and needed help getting dressed and getting into the bath due to lower limb muscle weakness. On examination calf and thigh hypertrophy was noted bilaterally, the latter being more prominent. He had good strength (5/5) in his neck, upper limb, abdominal and shoulder muscles. Accurate assessment of strength was difficult because of pain and cooperation; he appeared weak in the lower limbs with 3/5 power in his quadriceps, however timed rise from floor sitting position was 1.03 seconds and timed rise from lying was 1.5 seconds (both without a Gower's manoeuvre), both of which were within the normal range.
He had tight long flexors of his arms, hamstrings and gastrocnemius, but no swelling or restriction of his joints. Hyperpigmented patches were noted over the right knee and right thigh, but no rashes were seen; again this was thought to possibly be secondary to warm compression. During neuromuscular examination right lower limb assessment was limited by significant right knee pain and he was agitated due to pain. He was able to stand on his left leg but was incapable of maintaining his balance. He had good axial flexure strength in the antigravity range. Cranial nerve examination was normal, with no facial weakness. Over the next few months his pain became progressively worse, with the pain awakening him during the night and causing him to miss days off school.
Immunohistochemistry for dysferlin was negative on most fibres. A few fibres showed focal membranous staining. Internal staining for dysferlin was not seen. An extensive panel of other dystrophy-related proteins was normal (including dystrophin, sarcoglycans, alpha-dystroglycan, merosin, emerin, collagen VI, desmin). There was some sarcolemmal staining for utrophin. There was minimal focal membrane staining for MHC class I and no staining of capillaries with Membrane Attack Complex (MAC). A few fibres expressed developmental myosin.
A provisional diagnosis of LGMD type 2B was made and was subsequently confirmed on dysferlin muscle immunoblotting and gene sequencing, which revealed two heterozygous mutations in the DYSF gene (c.265C > T; p.Arg89X in exon 4 and c.4756C > T; p.ARG1586X in exon 43). Parental DYSF studies confirmed inheritance of one of these mutations from each parent. The clinical course over a 4 month follow up period showed waxing and waning of the leg pain, with no response to a brief course of oral prednisolone treatment. The mainstay of symptom control included regular non-steroidal analgesics and management by the pain control team.
A central feature of the presentation in this case was muscle pain. Severe muscle pain is not typically a predominant symptom of LGMD. However, of the different types, LGMD type 2I is most closely associated with this feature . Although patients with other subtypes (eg. LGMD type 2I, dystrophinopathies and facioscapulohumeral muscular dystrophy) can also present with leg pain, this is usually mild and following exertion. The aetiology of pain may be inflammatory or metabolic, and is thought to be related to hypertrophy or pseudohypertrophy of the calf muscles. Calf muscle atrophy, rather than hypertrophy, is a major feature of LGMD type 2B and pain does not typically predominate .
Comparison of idiopathic inflammatory myopathies and muscular dystrophies
Idiopathic inflammatory myopathies []
Muscular dystrophies *
Systemic symptoms and arthritis are common; rash. Systemic symptoms and arthritis are common. Onset often acute or subacute.
Selective patterns of muscle hypertrophy or atrophy, with longstanding insidious onset of motor functional difficulties
Pattern of weakness
Proximal, but neck flexor and abdominal weakness is a common early feature
Usually limb girdle or rarely axial or distal weakness depending on muscular dystrophy subtype
Serum CK levels
Typically moderately raised CK; can be normal or very high
Extremely high CK, often above 5,000 units
Typical muscle MRI features
Proximal muscle inflammation with high signal on T2 weighted STIR images 
Typically specific patterns of muscle involvement with abnormal signal on T1 weighted images in different muscular dystrophies
Typical muscle biopsy features
MHC – class 1 upregulation, inflammatory infiltrate (frequently peri-vascular), peri-fascicular muscle fibre atrophy and endothelial cell abnormalities 
Dystrophic features (fibre necrosis, regeneration, fibrosis and fat infiltration) with absence or reduction of specific protein/enzyme, depending on specific muscular dystrophy subtype.
Autosomal dominant, recessive or X-linked inheritance
Dysferlin deficiency on muscle immunostaining is the most pertinent feature for diagnosis of dysferlinopathies and the final confirmation is with genetic analysis of DYSF . However, loss of dysferlin staining is well recognised secondary phenomena in other limb girdle muscular dystrophies, most well characterised in mutations in caveolin-3 (LGMD 1C). Sequencing of this gene is challenging as it contains 55 coding exons, spans 150kb of genomic DNA  and mutational hotspots do not appear to exist [12, 13].
Our case describes an atypical case of LGMD type 2B, with extremely elevated CK levels and severe pain and swelling of a single knee joint, and MR imaging changes initially suggestive of an inflammatory myopathy with a monoarthritis. This report supports the need for a high index of suspicion for muscular dystrophies in order to provide an early diagnosis, initiate appropriate medical care in a timely fashion and to avoid unnecessary immunosuppression for a presumed diagnosis of inflammatory myopathy.
Written consent was obtained from the patient's mother for this publication.
We are grateful to the family to allow the publication of this report. Prof Kate Bushby's and the NCG Rare Neuromuscular Disorders Limb Girdle Muscular Dystrophy service's help in Dysferlin gene studies is gratefully acknowledged. The UK JDM Cohort Study is supported by grant funding from the Wellcome Trust UK.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.